Study: Frequency of inherited mutations linked to breast cancer are similar in Black and white women
Contents
At a glance | Clinical trials |
Study findings | Guidelines |
Strengths and limitations | Questions for your doctor |
What does this mean for me? | Resources |
In-depth |
STUDY AT A GLANCE
What is this study about?
Researchers wanted to know the frequency of harmful (pathogenic) mutations that are linked to cancer in Black and white women.
Why is this study important?
Black women are diagnosed with breast cancer at younger ages and are diagnosed more often with receptor-negative (ER-negative) or triple-negative breast cancers. It has been unclear whether these disparities are due in whole or part to differences in inherited mutations or other causes.
Research shows that Black women are less likely to have genetic testing, are less likely to be referred for genetic testing and have less access to care among other barriers such as different rates of insurance access, longer intervals between screening and lower rates of follow up (see prior XRAY reviews on this topic here and here).
A remaining question in this study was whether the frequency of inherited mutations varies between different racial groups.
This study indicates that there is no difference in the rate of inherited mutations among Black and white women. While overall mutation rates were found to be the same, differences in the rate of mutations in a few specific genes were seen: and mutations were seen more often in Black women than white women, and mutations were seen less often in Black women than white women.
The study researchers concluded that race should not be used to determine who is referred for genetic testing. Furthermore, they suggest that systemic racism may account for racial disparities in breast cancer diagnoses in Black women rather than genetic differences.
Study findings
- Black women and white women with breast cancer have a similar chance of having an in a gene that increases breast cancer risk (5.65% among Black women and 5.06% among white women).
- The chance of having an in a particular gene that increases breast cancer risk differed between Black women and white women. Black women were less likely to have a mutation and more likely to have a or mutation than white women.
- There was no difference in the frequency of inherited mutations between Black and white women when looking only at women with ER-positive breast cancer or only at women with ER-negative breast cancer.
- There was no difference in the frequency of inherited mutations between Black and white women who were diagnosed before age 50.
Strengths and limitations
Strengths
- This was a large study involving 29,233 women with breast cancer which allows researchers to be confident in their conclusions.
- Participants were not selected for participation based on their family history of cancer or age at diagnosis. In other words, they may or may not have had a family history of cancer and could have been diagnosed at any age. This is a good approach for reducing selection bias. (Selection bias occurs when groups differ due to factors other than the ones being studied.)
Limitations
- This study focused only on Black and white women. No information about Hispanic, Indigenous, Pacific Islander or Asian American women was provided. No information about other ethnic groups was provided (e.g., , Bahamian or Nigerian heritage, which are associated with higher rates of inherited mutations in breast cancer risk genes).
- This study looked only at women with breast cancer.
What does this mean for me?
- If you are a woman with breast cancer, your chance of having an in a gene that is linked to breast cancer is about 5% regardless of your race, family history or age at diagnosis. Early age at diagnosis and strong family history are linked to an increased risk of an .
- If you are a Black woman, you are as likely as white women to have an in a high-risk breast cancer gene.
- Black women have been historically referred for genetic testing less often than white women, despite having similar chances of having an . If you have a family history of cancer (including breast, ovarian, pancreatic and cancers), you may want to talk to your doctor about genetic counseling and testing.
This XRAY was reviewed by FORCE's Scientific Advisory Board.
Share your thoughts on this XRAY review by taking our brief survey.
posted 8/13/21
References
Domchek SM, Yao S, Chen F, et al. Comparison of the prevalence of pathogenic variants in cancer susceptibility genes in Black women and non-Hispanic white women with breast cancer in the United States. JAMA Oncology. 2021; 7(7): 1045–1050. doi:10.1001/jamaoncol.2021.1492.
Hu C, Hart SN, Gnanaolivu R, et al. A population-based study of genes previously implicated in breast cancer. New England Journal of Medicine. 2021; 384: 440-451. doi: 10.1056/NEJMoa2005936.
Disclosure
FORCE receives funding from industry sponsors, including companies that manufacture cancer drugs, tests and devices. All XRAYS articles are written independently of any sponsor and are reviewed by members of our Scientific Advisory Board prior to publication to assure scientific integrity.
This article is relevant for:
Non-Hispanic Black and white women with breast cancer
This article is also relevant for:
people with breast cancer
previvors
people newly diagnosed with cancer
people with a family history of cancer
Be part of XRAY:
IN-DEPTH REVIEW OF RESEARCH
Study background
Understanding the frequency of inherited mutations in genes that predispose people to cancer is helpful for guiding genetic screening. People with an have different surveillance and preventive options to consider with their doctors. For those who develop cancer, an may alter treatment choices and the risk of recurrence.
The Cancer Risk Estimates Related to Susceptibility (CARRIERS) study looked at a group of 32,247 women with breast cancer to determine the frequency of harmful (pathogenic or likely pathogenic) mutations compared to 32,544 women without breast cancer. The women were enrolled regardless of whether they had a family history of cancer or not. The researchers found that 5.03 percent of women with breast cancer had an that was associated with breast cancer risk while only 1.63 percent of women without breast cancer had one of these mutations. This is a comprehensive and definitive study.
Inherited mutations in the and genes were linked to a high chance of breast cancer—more than seven times that of people without inherited mutations in these genes. Mutations in were linked to four times the risk of breast cancer compared to women without mutations. Mutations in the , and genes were linked to a higher risk of ER-negative and , while mutations in the , CHD1 and genes were linked to a higher risk of ER-positive breast cancer.
Black women in the United States are more likely to be diagnosed with breast cancer at an early age (before 50) or with receptor-negative (ER-negative) or () than non-Hispanic white women. It was not known whether these differences were due to varying rates of inherited mutations or to other factors.
Research shows that Black women are less likely to have genetic testing, are less likely to be referred for genetic testing and have less access to care among other barriers such as different rates of insurance access, longer intervals between screening and lower rates of follow up
A remaining question in this study was whether the frequency of inherited mutations varies between different racial groups.
Because the CARRIERS study enrolled a large number of participants, including a substantial number of Black women, it was possible to ask this question and have statistical confidence in the result. Researchers looked at the self-reported race of the women with breast cancer who participated in the study and then determined the frequency of harmful mutations in Black and white women.
Researchers of this study wanted to know
Researchers wanted to know whether there was a difference in the frequency of inherited mutations linked to increased breast cancer risk among Black and white women.
Populations looked at in this study
This study evaluated information about 3,946 Black women and 25,287 non-Hispanic white women with breast cancer from the CARRIERS study. These women were enrolled between June 1993 and June 2020 regardless of their family history or age at breast cancer diagnosis, and self-reported their race and ethnicity. Among participants, the average age of Black women was 56 and of white women was 62. Black women and white women who were included in this study were not Hispanic.
All of the women participated in one of 12 studies that were included in the CARRIERS study [the Black Women's Health Study (HBWS), the Cancer Prevention Study II (CPSII), the California Teachers Study (CTS), the Multiethnic Cohort Study (MEC), the Nurses' Health Study (NHS), the Nurses' Health Study II (NHSII), the Women's Health Initiative (WHI), the Cancer Prevention Study (CPS3), Mayo Health Study (MMHS), the Mayo Clinic Breast Cancer Study (MCBCS), the Women's Circle of Health Study (WCHS) and the Wisconsin Women's Health Study (WWHS)].
Study design
Researchers looked at the from each participant for the presence of inherited mutations in any of 37 known or potential cancer risk genes. Twelve genes that are linked to elevated breast cancer risk were evaluated, including , , , , , , , , , , , and .
Researchers first compared the frequency of all Black women with an in a breast cancer gene to the frequency of all white women with an . They then looked for any difference in frequency of inherited mutations in the two groups based on age or estrogen-receptor status of the breast cancer.
Study findings
- Black women and white women have a similar chance of having an in a gene that increases breast cancer risk.
- 223 of 3,946 Black women (5.65%) had an in a high-risk breast cancer gene.
- 1,279 of 25,287 white women (5.06%) had an in a high-risk breast cancer gene.
- These frequencies are statistically similar.
- The chance of having an in a particular gene that increases breast cancer risk differed between Black women and white women. Black women were less likely to have a mutation and more likely to have a or mutation than non-Hispanic white women.
- 0.35% of Black women had a mutation in .
- 1.29% of white women had a mutation in .
- 1.8% of Black women had a mutation in .
- 1.24% of white women had a mutation in .
- 1.1% of Black women had a mutation in .
- 0.4% of white women had a mutation in .
- Black and white women had a similar chance of having a mutation in , , BARD, , , , , or .
- There was no difference in the frequency of inherited mutations between Black and white women based on estrogen-receptor status.
- Among women with ER-positive breast cancer:
- 4.38% of Black women had an .
- 4.38% of white women had an .
- Among women with ER-negative breast cancer:
- 9.28% of Black women had an .
- 8.08% of white women had an .
- Among women with ER-positive breast cancer:
- There was no difference in the frequency of inherited mutations between Black and non-Hispanic white women who were diagnosed before age 50.
- 8.83% of Black women had an .
- 10.04% of white women had an .
This study indicates that there is no difference in the rate of inherited mutations among Black and white women. While overall mutation rates were the same, differences in the rate of mutations of a few individual genes were seen; and mutations were seen more often in Black women and mutations were seen less often.
Strengths and Limitations
Strengths
- This was a large study involving 29,233 women (3,946 non-Hispanic Black women and 25,287 non-Hispanic white women). This enables researchers to be confident in their conclusions.
- Participants were not selected based on their family history of cancer or age at diagnosis. In other words, they may or may not have had a family history of cancer and they could have been diagnosed at any age. This is a good approach for reducing selection bias. (Selection bias occurs when groups differ due to factors other than the ones being studied.)
- A careful statistical analysis was done to determine whether any differences existed between the groups.
Limitations
- Information on family history and receptor status of breast cancers was missing for some participants.
- The number of women with mutations in some genes (e.g., and ) was small, limiting the conclusions that could be made.
- This study focused only on Black women and white women. No information about Hispanic, Indigenous, Pacific Islander or Asian American women was provided.
- This study looked only at women with breast cancer. It did not look at the frequency of mutations among women without breast cancer in the original CARRIERS study. The comparison between Black women with and without breast cancer and white women with and without breast cancer may be informative.
Context
This study further analyzes the findings of the CARRIERS study by looking at inherited mutations among Black women and white women. It builds on the prior observation that about 5 percent of women in the U.S. with breast cancer have an in a cancer gene. Black women are diagnosed at younger ages, and more often with ER-negative breast cancer. It is known that referral for genetic testing and access to care is reduced among Black women compared to white women. The contribution of genetic differences among Black women to this disparity was not known. This study indicates that race is not helpful for determining who should have genetic testing. Instead, other factors like family history, age at diagnosis (both well-described predictors of inherited mutations) should guide genetic testing referral.
Conclusions
No difference in the rate of inherited mutations was seen among Black and white women in this study. Black and white women did have a different frequency of mutations in a few individual genes: and mutations occurred more often in Black women and mutations occurred less often.
The study researchers concluded that race should not be an independent consideration for genetic testing. Furthermore, they suggested that systemic racism rather than genetic differences may account for racial disparities in breast cancer diagnoses in Black women.
Share your thoughts on this XRAY review by taking our brief survey.
posted 8/13/21
National Comprehensive Cancer Network guidelines regarding who should undergo genetic counseling and testing recommend speaking with a genetics expert about genetic testing if you have been diagnosed with breast cancer and any of the following apply to you:
- You have a blood relative who has tested positive for an
- You have any of the following:
- Breast cancer at age 50 or younger.
- Male breast cancer at any age.
- Ovarian cancer at any age.
- at any age.
- Two separate breast cancer diagnoses.
- Eastern European Jewish ancestry and breast cancer at any age.
- Lobular breast cancer and a family history of diffuse gastric cancer.
- breast cancer and are at high-risk for recurrence.
- Tumor testing shows a mutation in a gene that is associated with .
OR
- You have one or more close family members who have had:
- Young-onset or rare cancers.
- Breast cancer at age 50 or younger.
- .
- Male breast cancer, ovarian cancer, pancreatic cancer or cancer at any age.
- Two separate cancer diagnoses.
- prostate cancer or cancer that is high-risk or very-high-risk.
The American Society of Breast Cancer Surgeons (ASBrS) released guidelines in 2019 recommending that all women diagnosed with breast cancer have access to genetic testing for inherited mutations in breast cancer genes.
If you are uncertain whether you meet the guidelines above and you are interested in or considering genetic testing, you should speak with a cancer genetics expert.
Updated: 07/28/2023
- Should I have genetic testing for inherited mutations in cancer genes?
- How do I get genetic counseling?
- If I have an , what surveillance or preventive options do you recommend for me?
- I have a gene that is linked to an increased risk of breast cancer. Are there other cancer risks I should consider?
- My insurance won’t cover genetic testing. How can I get low-cost genetic testing?
The following clinical research studies focus on addressing in cancer.
- NCT04854304: Abbreviate or FAST Breast for Supplemental Breast Cancer Screening for Black Women at Average Risk and Dense Breasts. This study is looking at how effectively a FAST breast can successfully detect breast cancer in Black women with dense breasts.
- NCT03640208: Educate, Assess Risk and Overcoming Barriers to Colorectal Screening Among African Americans. This research will study a community-based intervention to educate and overcome barriers to screening among African Americans who are 45 years or older with no personal or family history of colorectal cancer or inflammatory bowel disease.
- NCT04392050: A Community-Based Educational Intervention to Improve Colorectal Cancer Screening. This study will look at what makes it easy or difficult for underserved populations to have colorectal cancer screenings, with a focus on African American, Latinx and Asian people.
Updated: 10/16/2024
Who covered this study?
Healio
Prevalence of mutations linked to breast cancer risk similar between Black, white patients This article rates 4.0 out of 5 stars
Science Magazine
Black and white women have same mutations linked to breast cancer risk This article rates 3.5 out of 5 stars
U.S. News and World Report
Race Doesn't Affect Risk for Genes That Raise Breast Cancer Risk This article rates 3.0 out of 5 stars
Medscape
Prevalence of Breast Cancer-Susceptibility Genes Similar in Black and White Women This article rates 3.0 out of 5 stars
Cancernetwork.com
Black and non-Hispanic White Women Found to Have No Differences in Genetic Risk for Breast Cancer This article rates 2.5 out of 5 stars